Breaking News Instant updates and real-time market news.

CELG

Celgene

$84.83

1.23 (1.47%)

, NVS

Novartis

$78.82

1.67 (2.16%)

10:23
07/12/18
07/12
10:23
07/12/18
10:23

PTAB decision on Gilenya positive for Celgene, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond expects the market to react positively with respect to Celgene (CELG) shares, at least initially, following the Patent Trial and Appeal Board decision regarding ozanimod competitor Gilenya from Novartis (NVS). Yesterday, the PTAB issued a decision that upholds validity of Gilenya's dosing patent in response to inter partes review petitions from multiple generic filers, Raymond tells investors in a research note. While this decision will likely be appealed, it opens up the possibility for Gilenya intellectual property runway out to 2027, when the dosing patent expire, the analyst adds. Raymond believes that not having a generic S1P class at launch for ozanimod is positive for Celgene. However, without the removal of first dose monitoring, ozanimod is not likely to be differentiated enough to make a difference, the analyst says, citing physician feedback. He keeps a Neutral rating on Celgene with a $95 price target. The stock in early trading is up 2% to $84.92.

CELG

Celgene

$84.83

1.23 (1.47%)

NVS

Novartis

$78.82

1.67 (2.16%)

  • 26

    Jul

CELG Celgene
$84.83

1.23 (1.47%)

07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
07/10/18
PIPR
07/10/18
NO CHANGE
PIPR
Neutral
Celgene raised prices on both Revlimid and Pomalyst by 5%, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Wolters Kluwer Health reports that Celgene increased its prices for Revlimid and Pomalyst by 5%, effective yesterday. The analyst, who pointed out that this is the first increase since October 2017 for both drugs, said the price hikes should provide some tailwind to Celgene's second half results. He maintains his Neutral rating on Celgene shares.
07/10/18
PIPR
07/10/18
DOWNGRADE
Target $52
PIPR
Neutral
Acceleron downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Acceleron Pharma (XLRN) to Neutral and lowered his price target for the shares to $52 from $55. Acceleron and partner Celgene (CELG) last night announced positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia, Tenthoff tells investors in a research note. The stock in premarket trading is up $6.10, or 13%, to $53.50. This is a nice second win for luspatercept, but Acceleron shares are not a buy at current valuation levels, the analyst contends. He believes luspatercept does not command the same market opportunity in beta thalassemia due to the expected approval of curative gene therapy by 2020. As such, Tenthoff lowered his penetration rates for luspatercept in beta thal to account for gene therapy competition. He says, however, that partner Celgene could acquire Acceleron, which presents a risk to his downgrade.
NVS Novartis
$78.82

1.67 (2.16%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/02/18
ROTH
07/02/18
NO CHANGE
Target $22
ROTH
Buy
Cryoport price target raised to $22 from $12.50 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Cryoport (CYRX) to $22 from $12.50 while reiterating a Buy rating on the shares. The analyst notes that the European Medicines Agency recommended "marketing authorizations" for therapies developed by two of Cryoport's clients, Gilead's (GILD) Yescarta and Novartis' (NVS) Kymriah. Baldry believes these two approvals roughly double the addressable market for the therapies and offer upside potential to our 2019 forecasts.
07/02/18
HCWC
07/02/18
NO CHANGE
Target $10
HCWC
Buy
Adamis price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert raised his price target for Adamis Pharmaceuticals (ADMP) to $10 after the company announced that Novartis (NVS) division Sandoz division will commercialize Symjepi. While the deal took longer than expected, the terms of a 50:50 split is better than anticipated, Kolbert tells investors in a research note. The analyst sees Sandoz as a "great partner" and reiterates a Buy rating on Adamis.
07/02/18
RILY
07/02/18
NO CHANGE
Target $7.5
RILY
Buy
Adamis price target raised to $7.50 from $6.25 at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva raised his price target for Adamis Pharmaceuticals (ADMP) to $7.50 after the company entered into a strategic partnership with Novartis (NVS) unit Sandoz. The analyst views the agreement as favorable and keeps a Buy rating on Adamis.

TODAY'S FREE FLY STORIES

13:11
10/23/18
10/23
13:11
10/23/18
13:11
General news
2-Yr Note Auction Coupon Rate data reported »

2-Yr Note Auction Coupon…

13:10
10/23/18
10/23
13:10
10/23/18
13:10
General news
2-Yr Note Auction Total Amount data reported »

2-Yr Note Auction Total…

XOM

Exxon Mobil

$79.26

-1.89 (-2.33%)

13:10
10/23/18
10/23
13:10
10/23/18
13:10
Periodicals
Exxon, Rosneft to build LNG plant with Japanese, Indian partners, Reuters says »

According to sources,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$86.62

-2 (-2.26%)

13:07
10/23/18
10/23
13:07
10/23/18
13:07
Hot Stocks
OCC assesses $100M civil money penalty against Capital One »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

WFC

Wells Fargo

$51.29

-0.35 (-0.68%)

13:05
10/23/18
10/23
13:05
10/23/18
13:05
Hot Stocks
Wells Fargo to hire new technology head to join Wells Fargo Operating Committee »

Wells Fargo announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

LEN

Lennar

$40.79

1.42 (3.61%)

13:05
10/23/18
10/23
13:05
10/23/18
13:05
Options
Lennar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$27.60

-0.17 (-0.61%)

13:01
10/23/18
10/23
13:01
10/23/18
13:01
Hot Stocks
Washington Federal names Thomas Kelley chairman »

Washington Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

SELB

Selecta Biosciences

$9.78

-3.59 (-26.85%)

, HZNP

Horizon Pharma

$18.70

-0.55 (-2.86%)

13:01
10/23/18
10/23
13:01
10/23/18
13:01
Recommendations
Selecta Biosciences, Horizon Pharma analyst commentary  »

Selecta stock reaction to…

SELB

Selecta Biosciences

$9.78

-3.59 (-26.85%)

HZNP

Horizon Pharma

$18.70

-0.55 (-2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 27

    Nov

T

AT&T

$32.70

0.04 (0.12%)

, BA

Boeing

$348.11

-7.87 (-2.21%)

13:00
10/23/18
10/23
13:00
10/23/18
13:00
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

T

AT&T

$32.70

0.04 (0.12%)

BA

Boeing

$348.11

-7.87 (-2.21%)

UPS

UPS

$113.87

-1.73 (-1.50%)

TMO

Thermo Fisher

$221.04

-4.71 (-2.09%)

GD

General Dynamics

$187.12

-2.94 (-1.55%)

NOC

Northrop Grumman

$301.05

-5.72 (-1.86%)

BSX

Boston Scientific

$35.83

-0.8 (-2.18%)

NSC

Norfolk Southern

$157.12

-6.82 (-4.16%)

ITW

Illinois Tool Works

$123.90

-3.5 (-2.75%)

SIRI

Sirius XM

$6.00

-0.025 (-0.42%)

HLT

Hilton

$68.48

-1.69 (-2.41%)

FCX

Freeport McMoRan

$11.52

-0.485 (-4.04%)

QSR

Restaurant Brands

$56.46

-0.19 (-0.34%)

NDAQ

Nasdaq

$80.88

-0.13 (-0.16%)

IVZ

Invesco

$20.96

-0.16 (-0.76%)

OC

Owens Corning

$47.39

-1.33 (-2.73%)

NYCB

New York Community Bancorp

$9.26

-0.12 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Dec

SIX

Six Flags

$64.08

-1.52 (-2.32%)

, TER

Teradyne

$32.00

-0.29 (-0.90%)

12:57
10/23/18
10/23
12:57
10/23/18
12:57
Earnings
Notable companies reporting after market close »

Notable companies…

SIX

Six Flags

$64.08

-1.52 (-2.32%)

TER

Teradyne

$32.00

-0.29 (-0.90%)

JNPR

Juniper

$27.65

-0.83 (-2.91%)

TSS

TSYS

$91.75

-1.72 (-1.84%)

EW

Edwards Lifesciences

$147.25

-2.23 (-1.49%)

COF

Capital One

$86.67

-1.95 (-2.20%)

ILMN

Illumina

$309.61

-7.61 (-2.40%)

CB

Chubb

$126.79

-0.34 (-0.27%)

TXN

Texas Instruments

$98.85

-0.89 (-0.89%)

NAVI

Navient

$12.27

-0.26 (-2.08%)

IRBT

iRobot

$90.75

-0.03 (-0.03%)

HA

Hawaiian Holdings

$33.24

-1.36 (-3.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 09

    Nov

SBUX

Starbucks

$59.10

0.19 (0.32%)

12:55
10/23/18
10/23
12:55
10/23/18
12:55
Periodicals
Starbucks opens first sign language store in D.C., AP reports »

Starbucks has opened a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 13

    Dec

TTWO

Take-Two

$118.48

-2.03 (-1.68%)

, SNE

Sony

$54.73

-1.05 (-1.88%)

12:54
10/23/18
10/23
12:54
10/23/18
12:54
OnTheFly
Game On: Morgan Stanley sees big changes to gaming console market »

NEW RELEASES: The major…

TTWO

Take-Two

$118.48

-2.03 (-1.68%)

SNE

Sony

$54.73

-1.05 (-1.88%)

MSFT

Microsoft

$106.92

-2.72 (-2.48%)

UBSFY

Ubisoft

$0.00

(0.00%)

NTDOY

Nintendo

$0.00

(0.00%)

ATVI

Activision Blizzard

$68.32

-1.46 (-2.09%)

EA

Electronic Arts

$99.12

-2.25 (-2.22%)

GOOG

Alphabet

$1,090.88

-9.64 (-0.88%)

GOOGL

Alphabet Class A

$1,100.71

-10.49 (-0.94%)

AMZN

Amazon.com

$1,744.10

-44.9 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 13

    Nov

  • 28

    Nov

  • 03

    Mar

SELB

Selecta Biosciences

$10.01

-3.36 (-25.13%)

12:54
10/23/18
10/23
12:54
10/23/18
12:54
Hot Stocks
Selecta Biosciences slides after new interim data from Phase 2 trial of SEL-212 »

Shares of Selecta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SCYX

Scynexis

$0.94

-0.0491 (-4.99%)

12:53
10/23/18
10/23
12:53
10/23/18
12:53
Recommendations
Scynexis analyst commentary  »

Scynexis shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AKAM

Akamai

$64.21

-1.04 (-1.59%)

12:53
10/23/18
10/23
12:53
10/23/18
12:53
Hot Stocks
Verimatrix acquires the assets of AIS from Akamai »

Verimatrix, a specialist…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 01

    Nov

  • 13

    Nov

ASTE

Astec

$38.67

-8.65 (-18.28%)

12:50
10/23/18
10/23
12:50
10/23/18
12:50
Downgrade
Astec rating change  »

Astec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

AAL

American Airlines

$31.72

-0.45 (-1.40%)

12:50
10/23/18
10/23
12:50
10/23/18
12:50
Options
10K American Airlines Nov 32 calls bought for $1.25, tied to 400K shares »

10K American Airlines Nov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SELB

Selecta Biosciences

$9.80

-3.57 (-26.70%)

12:47
10/23/18
10/23
12:47
10/23/18
12:47
Recommendations
Selecta Biosciences analyst commentary  »

Selecta Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SPY

SPDR S&P 500 ETF Trust

$271.39

-3.63 (-1.32%)

, SPX

S&P 500

$0.00

(0.00%)

12:47
10/23/18
10/23
12:47
10/23/18
12:47
Periodicals
Top White House advisor Kudlow says new tax cuts may be delayed, Hill says »

According to the Hill, On…

SPY

SPDR S&P 500 ETF Trust

$271.39

-3.63 (-1.32%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTE

Astec

$38.42

-8.9 (-18.81%)

12:45
10/23/18
10/23
12:45
10/23/18
12:45
Downgrade
Astec rating change  »

Astec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

12:45
10/23/18
10/23
12:45
10/23/18
12:45
General news
FX Action: USD-CAD »

FX Action: USD-CAD fell…

KHC

Kraft Heinz

$55.92

-0.3 (-0.53%)

12:41
10/23/18
10/23
12:41
10/23/18
12:41
Periodicals
Kraft Heinz to sell Indian asset portfolio to Zydus, Bloomberg reports »

Kraft Heinz has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 01

    Nov

V

Visa

$137.16

-3.48 (-2.47%)

12:40
10/23/18
10/23
12:40
10/23/18
12:40
Options
Visa calls lead puts 2:1 in heavy option volume as earnings approach »

Visa calls lead puts 2:1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 13

    Nov

  • 26

    Nov

  • 29

    Jan

LH

LabCorp

$166.46

-2.9 (-1.71%)

12:35
10/23/18
10/23
12:35
10/23/18
12:35
Recommendations
LabCorp analyst commentary  »

LabCorp recent selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

ABX

Barrick Gold

$13.36

0.27 (2.06%)

, GOLD

Randgold

$83.26

1.47 (1.80%)

12:35
10/23/18
10/23
12:35
10/23/18
12:35
Hot Stocks
Barrick Gold says Glass Lewis urges holders vote for merger resolutions »

Barrick Gold Corporation…

ABX

Barrick Gold

$13.36

0.27 (2.06%)

GOLD

Randgold

$83.26

1.47 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.